Celularity Inc. Faces Delisting Notice

Ticker: CELUW · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1752828

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-notice

Related Tickers: CELU

TL;DR

CELU got a delisting warning, stock might get kicked off the exchange.

AI Summary

Celularity Inc. received a notice on August 22, 2024, indicating it failed to meet a continued listing rule or standard for its stock. This filing is a Form 8-K reporting this critical event to the SEC.

Why It Matters

Failure to meet listing standards can lead to delisting from major exchanges, significantly impacting stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — Receiving a notice of failure to meet continued listing standards is a direct precursor to potential delisting, posing a significant risk to the company's market presence.

Key Players & Entities

FAQ

What specific continued listing rule or standard did Celularity Inc. fail to meet?

The filing states that Celularity Inc. received a notice of "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard" but does not specify which particular rule was violated.

What is the date of the notice regarding the failure to meet listing standards?

The earliest event reported, which includes the notice, is dated August 22, 2024.

What is Celularity Inc.'s Commission File Number?

Celularity Inc.'s Commission File Number is 001-38914.

What was Celularity Inc.'s former company name?

Celularity Inc.'s former company name was GX Acquisition Corp.

What is the company's state of incorporation?

Celularity Inc. is incorporated in Delaware.

Filing Stats: 749 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-08-23 17:15:22

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC. Date: August 23, 2024 By: /s/ Robert J. Hariri Robert J. Hariri, M.D., Ph.D. Chairman and CEO

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing